Online inquiry

IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12818MR)

This product GTTS-WQ12818MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MASP2 gene. The antibody can be applied in Atypical hemolytic uremic syndrome (aHUS) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_006610.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10747
UniProt ID O00187
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ12818MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ74MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ13558MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ144MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA 124I_WX-G250
GTTS-WQ6501MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CX-072
GTTS-WQ6441MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ8978MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ILV-094
GTTS-WQ785MR IVTScrip™ mRNA-Anti-AXL, Ab-2(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Ab-2
GTTS-WQ9416MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW